WAYNE, Pa. — August 27, 2025 — Leads & Copy — Avalo Therapeutics, Inc. (Nasdaq: AVTX) will participate in several investor conferences in September, including the Cantor Global Healthcare Conference on September 3, the H.C. Wainwright 27th Annual Global Investment Conference on September 9, and the Stifel 2025 Virtual Immunology and Inflammation Forum on September 15. Live webcasts and replays, when available, can be found in the Investors section of the Avalo Therapeutics website.
Avalo Therapeutics is a clinical stage biotechnology company focused on developing IL-1β-based treatments for immune-mediated inflammatory diseases. Its lead asset, AVTX-009, is in a Phase 2 clinical trial for hidradenitis suppurativa (HS). AVTX-009 is a humanized monoclonal antibody that neutralizes the activity of interleukin-1β (IL-1β), a pro-inflammatory cytokine involved in various human diseases.
Christopher Sullivan, CFO of Avalo Therapeutics, can be reached at ir@avalotx.com or 410-803-6793.
Lauren Glaser of Meru Advisors can be reached at lglaser@meruadvisors.com.
Source: Avalo Therapeutics
